RhBMP-2 Officially Approved For Marketing in Indonesia, Accelerating Jiuyuan Gene’s Overseas Expansion

On November 15, Jiuyuan Gene (2566.HK) announced that its bone repair product rhBMP-2(a bo ne repair material containing rhBMP-2) had obtained official marketing approval from the Indonesian Ministry of Health. This marks rhBMP-2's first entry into the ASEAN market, representing a crucial step forward in the company's global expansion strategy.

As China's first approved and commercialized bone repair material incorporating recombinant human rhBMP-2, rhBMP-2 boasts high technical barriers. Its development requires dual capabilities in recombinant protein biopharmaceutical manufacturing and medical device design for carrier materials.

In the orthopedics sector, the company's product pipeline development is gaining momentum. The next-generation bone repair material JY23(a multipotent biological bone containing rhBMP-2) completed registration testing in the first half of this year. Mid-term results of biological trials demonstrate the product's safety and efficacy, with a marketing application expected to be filed in the first half of 2026.

With over three decades of expertise in genetic engineering pharmaceuticals, Jiuyuan Gene has focused on this field since its establishment in 1993. It possesses more than 30 years of experience in R&D, manufacturing and commercialization of biopharmaceuticals and medical devices, forming a dual-drive R&D system integrating biopharmaceuticals and medical devices. Its core products cover high-growth sectors including bone repair materials, GLP-1-based drugs and long-acting biological agents.

While advancing its internationalization drive, Jiuyuan Gene will continue to uphold its mission of "Taking gene engineering as orientation, Rendering service to human health". It will accelerate the R&D and industrialization of core products, striving to make greater contributions to the development of the biopharmaceutical industry.